Nilotinib in advanced gastrointestinal stromal tumors after imatinib and sunitinib therapy

Area of Science:

• Oncology
• Gastrointestinal Oncology
• Pharmacology

Background:

• Metastatic gastrointestinal stromal tumor (GIST) presents challenges in treatment, especially after failure of standard therapies like imatinib and sunitinib.
• Identifying effective salvage therapies is crucial for improving outcomes in advanced GIST patients.

Purpose of the Study:

• To evaluate the efficacy and safety of nilotinib in patients with metastatic GIST who were refractory to prior imatinib and sunitinib treatment.
• To assess treatment response, duration of response, and adverse events associated with nilotinib in this patient population.

Main Methods:

• A compassionate use program was utilized to treat patients with advanced GIST.
• Inclusion criteria required prior treatment with imatinib and sunitinib, with documented disease progression or intolerance.
• Patient demographics, clinical characteristics, nilotinib response, duration of response, and adverse events were analyzed.

Main Results:

• Data from 7 patients treated with nilotinib for at least 30 days were analyzed.
• One patient achieved a complete response, one a partial response, two had stable disease, and three experienced progressive disease.
• No life-threatening adverse events were reported; grade 2-3 asthenia was observed in three patients. No significant electrocardiographic changes occurred.

Conclusions:

• Nilotinib demonstrates clinical activity in metastatic gastrointestinal stromal tumor (GIST) patients resistant to imatinib and sunitinib.
• Nilotinib may serve as a viable alternative treatment option for advanced GIST following failure of standard therapies.